155 related articles for article (PubMed ID: 11190577)
1. Modulation of protein kinase C in antitumor treatment.
Hofmann J
Rev Physiol Biochem Pharmacol; 2001; 142():1-96. PubMed ID: 11190577
[TBL] [Abstract][Full Text] [Related]
2. PKC-independent modulation of multidrug resistance in cells with mutant (V185) but not wild-type (G185) P-glycoprotein by bryostatin 1.
Spitaler M; Utz I; Hilbe W; Hofmann J; Grunicke HH
Biochem Pharmacol; 1998 Oct; 56(7):861-9. PubMed ID: 9774148
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase C isozymes as potential targets for anticancer therapy.
Hofmann J
Curr Cancer Drug Targets; 2004 Mar; 4(2):125-46. PubMed ID: 15032665
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase C: a worthwhile target for anticancer drugs?
Caponigro F; French RC; Kaye SB
Anticancer Drugs; 1997 Jan; 8(1):26-33. PubMed ID: 9147607
[TBL] [Abstract][Full Text] [Related]
5. Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C.
Sachs CW; Safa AR; Harrison SD; Fine RL
J Biol Chem; 1995 Nov; 270(44):26639-48. PubMed ID: 7592889
[TBL] [Abstract][Full Text] [Related]
6. Anticancer drug-mediated induction of multidrug resistance-associated genes and protein kinase C isozymes in the T-lymphoblastoid cell line CCRF-CEM and in blasts from patients with acute lymphoblastic leukemias.
Beck JF; Brügger D; Brischwein K; Liu C; Bader P; Niethammer D; Gekeler V
Jpn J Cancer Res; 2001 Aug; 92(8):896-903. PubMed ID: 11509123
[TBL] [Abstract][Full Text] [Related]
7. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs.
Chaudhary PM; Roninson IB
J Natl Cancer Inst; 1993 Apr; 85(8):632-9. PubMed ID: 8096875
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase C effectors bind to multidrug ABC transporters and inhibit their activity.
Conseil G; Perez-Victoria JM; Jault JM; Gamarro F; Goffeau A; Hofmann J; Di Pietro A
Biochemistry; 2001 Feb; 40(8):2564-71. PubMed ID: 11327879
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation.
Courage C; Budworth J; Gescher A
Br J Cancer; 1995 Apr; 71(4):697-704. PubMed ID: 7710931
[TBL] [Abstract][Full Text] [Related]
10. The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells.
Stanwell C; Gescher A; Bradshaw TD; Pettit GR
Int J Cancer; 1994 Feb; 56(4):585-92. PubMed ID: 8112895
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of novel human lung carcinoma cell lines selected for resistance to anti-neoplastic analogues of staurosporine.
Courage C; Bradder SM; Jones T; Schultze-Mosgau MH; Gescher A
Int J Cancer; 1997 Nov; 73(5):763-8. PubMed ID: 9398059
[TBL] [Abstract][Full Text] [Related]
12. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance.
Gekeler V; Boer R; Uberall F; Ise W; Schubert C; Utz I; Hofmann J; Sanders KH; Schächtele C; Klemm K; Grunicke H
Br J Cancer; 1996 Sep; 74(6):897-905. PubMed ID: 8826855
[TBL] [Abstract][Full Text] [Related]
13. Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells.
Scala S; Dickstein B; Regis J; Szallasi Z; Blumberg PM; Bates SE
Clin Cancer Res; 1995 Dec; 1(12):1581-7. PubMed ID: 9815959
[TBL] [Abstract][Full Text] [Related]
14. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2.
Wang S; Vrana JA; Bartimole TM; Freemerman AJ; Jarvis WD; Kramer LB; Krystal G; Dent P; Grant S
Mol Pharmacol; 1997 Dec; 52(6):1000-9. PubMed ID: 9396780
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
Dean N; McKay R; Miraglia L; Howard R; Cooper S; Giddings J; Nicklin P; Meister L; Ziel R; Geiger T; Muller M; Fabbro D
Cancer Res; 1996 Aug; 56(15):3499-507. PubMed ID: 8758918
[TBL] [Abstract][Full Text] [Related]
16. Potent induction of human colon cancer cell uptake of chemotherapeutic drugs by N-myristoylated protein kinase C-alpha (PKC-alpha) pseudosubstrate peptides through a P-glycoprotein-independent mechanism.
Bergman PJ; Gravitt KR; Ward NE; Beltran P; Gupta KP; O'Brian CA
Invest New Drugs; 1997; 15(4):311-8. PubMed ID: 9547673
[TBL] [Abstract][Full Text] [Related]
17. The involvement of protein kinase C isoenzymes alpha, epsilon and zeta in the sensitivity to antitumor treatment and apoptosis induction.
Spitaler M; Wiesenhofer B; Biedermann V; Seppi T; Zimmermann J; Grunicke H; Hofmann J
Anticancer Res; 1999; 19(5B):3969-76. PubMed ID: 10628339
[TBL] [Abstract][Full Text] [Related]
18. An N-myristoylated protein kinase C-alpha pseudosubstrate peptide that functions as a multidrug resistance reversal agent in human breast cancer cells is not a P-glycoprotein substrate.
Bergman PJ; Gravitt KR; O'Brian CA
Cancer Chemother Pharmacol; 1997; 40(5):453-6. PubMed ID: 9272125
[TBL] [Abstract][Full Text] [Related]
19. Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes alpha and theta.
Gill PK; Gescher A; Gant TW
Eur J Biochem; 2001 Aug; 268(15):4151-7. PubMed ID: 11488907
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase C inhibitors.
Swannie HC; Kaye SB
Curr Oncol Rep; 2002 Jan; 4(1):37-46. PubMed ID: 11734112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
